The global colorectal cancer therapeutics market is anticipated to grow at a CAGR of 5.8% during the forecast period (2023-2030). The market growth is attributed to increasing number of grants to expand quality initiatives focused on enhancing biomarker-directed therapy in metastatic colorectal cancer. In August 2023, the National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) received the new grants to improve quality initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer. Fight Colorectal Cancer (Fight CRC) collaborated with NCCN and Pfizer, Inc in the grant process; Pfizer provided funding and oversee the projects.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/colorectal-cancer-therapeutics-market-size

Further, the growing FDA approvals and emergence of more front-line therapies are also contributing to the market growth. In January 19, 2023, the Food and Drug Administration (FDA) granted accelerated approval to tucatinib (Tukysa, Seagen Inc.) in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. There are different mutations within BRAF, but the one with FDA-approved treatment in colorectal cancer is BRAF V600E. This mutation is a specific variation in the BRAF protein. In cells with this mutation, BRAF always turn on the MEK protein. In September 2021, Eli Lilly and Company received the US FDA granted approval of a new indication for ERBITUX® (cetuximab injection) in combination with BRAFTOVI® (encorafenib), marketed by Pfizer, Inc., for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Market Coverage

The market number available for – 2022-2030
Base year- 2022
Forecast period- 2023-2030
Segment Covered- 

o          By Types of Colorectal Cancer

o          By Therapy

o          By End user

Regions Covered-

o          North America

o          Europe

o          Asia-Pacific

o          Rest of the World

Competitive Landscape- includes, Eli Lilly and Co., Genentech, Inc., Ipsen Pharma, Regeneron Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd., and others.

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
Who is the leader in the market?
How are players addressing challenges to sustain growth?
Where is the investment opportunity?

Global Colorectal Cancer Therapeutics Market Report Segment

By Types of colorectal cancer

Colorectal adenocarcinoma
Gastrointestinal carcinoid tumors
Others (Primary colorectal lymphomas, Gastrointestinal stromal tumors)

By Therapy

Immunotherapy
Chemotherapy
Radiation therapy
Others (Targeted therapy)

By End-User 

Hospitals
Clinics

A full report of Colorectal Cancer Therapeutics Market available @ https://www.omrglobal.com/industry-reports/colorectal-cancer-therapeutics-market-size

Company Profiles

Abbott Laboratories
Amgen, Inc.
Bayer AG
Beckman Coulter, Inc.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co.
Clinical Genomics Technologies Pvt. Ltd.
EDP Biotech Corp.
Epigenomics AG
Exact Sciences Corp.
Genomictree Co., Ltd.
IMV Inc.

 Reasons to Buying From us –

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Media Contact:

Contact Person: Mr. Anurag Tiwari

Email: [email protected]

Contact no: +91 780-304-0404

Company Name: Orion Market Research